The modern antimycotic era began with the introduction of griseofulvin in the 1950's, which had a tremendous impact on the management of dermatophytoses. Subsequent advances in therapy have lowered our threshold to treat recalcitrant cutaneous mycoses, such as onychomycosls. Newer generation antifungals including the triazoles, itraconazole and fluconazole, as well as the allylamine, terbinafine, may significantly reduce the prevalence of onychomycosis, as fungal nails are no longer incurable. The AIDS epidemic has been associated with an increase in the number of cutaneous and systemic mycotic infections. In spite of recent advances, organisms recalcitrant or resistant to therapy are common. Newer antifungal agents, improved diagnostic techniques, and standardization of fungal susceptibility testing are required to adequately treat patients with systemic and cutaneous mycoses. © 1995, The Japanese Society for Medical Mycology. All rights reserved.